Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Triiodothyronine (T3) in Metastatic Breast Cancer
NCT03787303Phase 2Terminated
- Sponsor
- Aultman Health Foundation
- Start
- Mar 2019
- Primary completion
- Mar 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of liothyronine in breast cancer, sponsored by Aultman Health Foundation. Started Mar 2019; status: terminated.
02
Drugs
liothyronine
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT03787303.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03787303.